Dong-A ST Faces New Wave Of Change As It Challenges Norms
Park Looks To Shake Up 'Outdated' R&D Approaches
Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.
You may also be interested in...
Korean biopharma companies and the government are making diverse efforts to collaborate and seek growth to overcome limited resources and capital, as well as a tough investment environment.
Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.